Q1 2023 results - Tuesday, April 25, 2023
Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Interim financial report (PDF 0.3 MB)
Download the interactive presentation (PDF 3.4 MB)
Download the podcast (MP3 34 MB)
Read the presentation transcript
Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)
| Key figures1 | Q1 2023 (USD m) |
Q1 2022 (USD m) |
% change (USD/cc) |
|---|---|---|---|
| Net sales | 12,953 | 12,531 | 3 (cc: 8) |
| Operating income | 2,856 | 2,852 | 0 (cc: 9) |
| Net income | 2,294 | 2,219 | 3 (cc: 14) |
| EPS (USD) | 1.09 | 1.00 | 9 (cc: 20) |
| Free cash flow2 | 2,720 | 1,392 | 95 |
Core |
|||
| Operating income | 4,413 | 4,083 | 8 (cc: 15) |
| Net income | 3,614 | 3,251 | 11 (cc: 18) |
| EPS (USD) | 1.71 | 1.46 | 17 (cc: 25) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- Effective January 1, 2023, Novartis revised its definition of free cash flow, to define free cash flow as net cash flows from operating activities less purchases of property, plant and equipment. To aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. See page 35 of the Condensed Interim Financial Report.